Ablynx and AbbVie sign inflammatory disease agreement
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged AbbVie, Ablynx, ALX-0061, Belgium, clincal trials, Ed Moses, Flanders Biotech, Humira, Luxembourg, Merck Serono, methotrexate, monoclonal antibody, Netherlands, Phase II, rheumatoid arthritis, systemic lupus erythematosus
Leave a comment
Biogen & Amicus partner for new Parkinson’s Drug Hunt
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged A2A agonists, Amicus Therapeutics, AstraZeneca, Biogen IDEC, BMS, Bristol-Myers Squibb, Isis Pharmaceuticals, John Crowley, Merck, multiple neurological targets, neurodegenerative, Parkinson’s disease, Tufts University, Vanderblit Center for Neurodegenerative Drug Discovery
Leave a comment
Liftstream Life Science Newsletter September Edition
The 1 year anniversary edition of Liftstream’s monthly newsletter contains:
Posted in Pharmaceutical business
Leave a comment
Onyx deal signals broader interest in orphan drugs
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Aegerion, Alexion, Amgen, BioMarin, Bloomberg, Breakthrough Therapy, Catalyst Pharmaceutical Partners, Chiesi, Chiesi Farmaceutici, EMA, FDA, Flemming Ornskov, Human Genetic Therapies, Jean-Jacques Bienaimé, Kamada, Kyprolis, life sciences, lysosomal storage diseases, M&A, Nexavar, NPS Pharmaceuticals, Onyx, Orphan drugs, pharmaceutical industry, rare diseases, regenerative medicine, Roche, San Francisco, Sarepta, Shire, speciality pharma, Ugo di Francesco, uniQure, Zymenex
Leave a comment
BioMerieux completes purchase of BioFire
Authored by James Sheppard
Biogen and Isis cement alliance with new $100m pact
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged alliance, antibody technology, antisense technology, Biogen IDEC, clinical study, Corporate Development and Partnerships, Isis Pharmaceuticals, ISIS-APOCIII Rx, neurodegenerative disease, partnership, partnerships, Pipeline, platform technology, Stanley Crooke
Leave a comment
UK aiming to boost regenerative medicine
Authored by James Sheppard
Posted in M&A Finance and Funding
Tagged cell sorter, Cell Therapy, commercialisation, David Willets, development, funding, London Biotech, One Nucleus, Oxford Biotech, regenerative medicine, research, science, Scottish Centre for Regenerative Medicine, stem cell research, Stevenage Biotech, UCL Institute of Ophthalmology, UK, UK government, UK Regenerative Medicine Platform, UKRMP
Leave a comment
DRI Capital raises third fund for royalty investments
Authored by Karl Simpson
Posted in M&A Finance and Funding
Tagged Academia, Behzad Khosrowshahi, biotech, Cubicin, DRI Capital, Drug Royalty Corporation, Drug Royalty III private equity fund, Enbrel, Myozyme, pharma, pharmaceutical royalties, regulatory approval, Remicade, Royalties, Sensipar, Simponi, Soliris, Stelara, Synagis, Tysabri, Xolair
Leave a comment
